Angiotensin receptor antagonism and angiotensin converting enzyme inhibition improve diastolic dysfunction and Ca2+-ATPase expression in the sarcoplasmic reticulum in hypertensive cardiomyopathy

Journal of Hypertension

Volumn 15, Issue 9, 1997, Pages 1001-1009

  Flesch, Markus ^a   Schiffer, Frank ^a   Zolk, Oliver ^a   Pinto, Yigal ^a   Stasch, Johannes Peter ^b   Knorr, Andreas ^b   Ettelbrück, Sylvia ^a   Böhm, Michael ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b BAYER AG   (Germany)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin receptor antagonists; Cardiac hypertrophy; Diastolic dysfunction; Renin angiotensin system; Sarcoplasmic reticulum Ca2+ ATPase

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN I; ATRIAL NATRIURETIC FACTOR; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MESSENGER RNA;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; ENZYME ASSAY; GENE EXPRESSION; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; IMMUNOBLOTTING; NONHUMAN; NORTHERN BLOTTING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SARCOPLASMIC RETICULUM; TRANSGENIC ANIMAL;

EID: 0030765865     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199715090-00011     Document Type: Article

References (50)

1. Kannel WB, Castelli WP, McNamara PM, McKee PA, Feinleib M: Role of blood pressure in the development of congestive heart failure: the Framingham Study. N Engl J Med 1972, 287:781-787.
2. Pfeffer MA, Reffer JM, Steinberg C, Finn P: Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 1985, 72:406-412.
3. Hirsch AT, Talsness CE, Smith AD, Schunkert H, Ingelfinger JR, Dzau VJ: Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure. Circulation 1992, 86:1566-1574.
4. Dunn FG, Oigman W, Ventura HO, Messerli FH, Kobrin I, Fohlich ED: Enalapril improves systemic and renal hemodynamic and allows regression of left ventricular mass in essential hypertension. Am J Cardiol 1984, 53:105-108.
5. Linz W, Schoelkens W, Ganten D: Converting enzyme inhibition specifically prevents the development and induces the regression of cardiac hypertrophy in rats. Clin Exp Hypertens 1989, 11:1325-1350.
6. Pfeffer MA, Braunwald E: Ventricular remodeling after myocardial infarction: experimental observations and clinical implictions. Circulation 1990, 81:1161-1172.
7. Cruickshank JM, Lewis J, Moore V, Dodd C: Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 1992, 6:85-90.
8. Böhm M, Castellano M, Agabiti-Rosei E, Flesch M, Paul M, Erdmann E: Dose-dependent dissociation of ACE-inhibitor effects on blood pressure, cardiac hypertrophy and β-adrenergic signal transduction. Circulation 1995, 92:3006-3013.
9. Beuckelmann DJ, Näbauer M, Erdmann E: Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 1992, 85:1046-1055.
10. Bonow RO, Udelson JE: Left ventricular diastolic dysfunction as a cause of congestive heart failure. Ann Intern Med 1992, 117:502-510.
11. Grossman W, McLauria WT: Diastolic dysfunction in congestive heart failure. N Engl J Med 1991, 325:1557-15634.
12. 2+ATPase gene in pressure overload-induced cardiac hypertrophy in the rat Circ Res 1990, 66:554-564.
13. 2+-ATPase in failing and nonfailing human myocardium. Circ Res 1994, 75:434-442.
14. Arai M, Alpert NR, MacLennan DH, Barton P, Penasamy M: Alterations in sarcoplasmic reticulum gene expression in human heart failure. Circ Res 1993, 72:463-469.
15. Schwinger RHG, Böhm M, Erdmann E: Inotropic and lusitropic dysfunction in myocardium from patients with dilated cardiomyopathy. Am Heart J 1992, 123:116-128.
16. Chiu AT, McCall DE, Price WA, Wong PC, Carini DJ, Duncia JV, et al.: Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990, 252:711-715.
17. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A: Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990, 265:22348-22357.
18. Zisman LS, Abraham TW, Meixell GE, Vamvakias BN, Quaife RW, Lowes BD, et al.: Angiotensin II formation in the intact human heart. J Clin Invest 1995, 95:1490-1498.
19. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A: Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990, 66:883-890.
20. Husain A: The chymase-angiotensin system in humans. J Hypertens 1993, 11:1155-1159.
21. Mimran A, Targhetta R, Laroche B: The antihypertensive effect of captopril, evidence of an influence of kinins. Hypertension 1980, 2:732-737.
22. Campbell DJ, Kladis A, Vaelentijn AJ: Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol 1995, 26:233-240.
23. Linz W, Schölkens BA: A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol 1992, 105:771-772.
24. Mullins J, Peters J, Ganten D: Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 1990, 344:541-544.
25. Bachmann S, Peters J, Engler E: Transgenic rats carrying the mouse renin 2-gene: morphologic characterization of a low-renin hypertension model. Kidney Int 1992, 41:24-36.
26. Paul M, Pinto YM, Schunkert H, Ganten D, Böhm M: Activation of the renin-angiotensin system in heart failure and hypertrophy - studies in human hearts and transgenic rats. Eur Heart J 1994, 15 (suppl D):63-67.
27. Böhm M, Moll M, Schmid B, Paul M, Ganten D, Castellano M, et al.: β-Adrenergic neuroeffector mechanisms in cardiac hypertrophy of renin transgenic rats. Hypertension 1994, 24:653-662.
28. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate[-]phenol[-]chloroform extraction. Anal Biochem 1987, 162:156-159.
29. 2+-dependent ATPase from rabbit muscle sarcoplasmic reticulum, deduced from its complementary DNA sequence. Nature 1985, 316:696-700.
30. Oikawa S, Imai M, Ueno A, Tanaka S, Noguchi T, Nakazato H, et al.: Cloning and sequence analysis of cDNA encoding a precursor for human atrial natriuretic polypeptide. Nature 1984, 309:724-726.
31. Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of protein from polyacrylamide gels to nitrocellulose sheets: procedures and some applications. Proc Natl Acad Sci USA 1979, 76:4350-4354.
32. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurements with the folin phenol reagent. J Biol Chem 1951, 193:265-275.
33. Dixon TF, Purdom M: Serum 5′ nucleotidase. J Clin Pathol 1954, 7:341-351.
34. Crazier J, Ikram H, Awan N: Losartan in heart failure: hemodynamic effects and tolerability. Circulation 1995, 91:6691-6697.
35. Dickstein K, Chang P, Willenheimer R, Haunso S, Remes J, Hall C, et al.: Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 1995, 26:438-445.
36. Kojima M, Shiojima I, Yamazaki T, Komuro I, Yunzeng Z, Ying W, et al.: Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. Circulation 1994, 89:2204-2211.
37. Ruzicka M, Yuan B, Leenen FHH: Effects of enalapril versus losartan on regression of volume overload-induced vetricular myocardium. Circulation 1994, 90:484-491.
38. Capasso JM, Li P, Meggs L, Herman MV, Anversa P: Efficacy of angiotensin-converting enzyme inhibition and AT, receptor blockade on cardiac pump performance after myocardial infarction in rats. J Cardiovasc Pharmacol 1994, 23:584-593.
39. Makino N, Tomoji H, Sugano M, Dixon IMC, Yanaga T: Regression of hypertrophy after myocardial infarction is produced by the chronic blockade of angiotensin type 1 recptor in rats. J Mol Cell Cardiol 1996, 28:507-517.
40. Schieffer B, Wirger A, Meybrunn M, Seitz S, Holtz J, Riede UN, et al.: Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 1994, 89:2273-2282.
41. Yonezawa T, Umemoto S, Fujii A, Katayama K, Matsuzaki M: Comparative effects of type 1 angiotensin II-receptor blockade with angiotensin-converting-enzyme inhibitor on left ventricular distensibility and collagen metabolism in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1996, 27:119-124.
42. 1-receptor blockade. Cardiovasc Res 1996, 31:758-768.
43. Sadoshima J, Izumo S: Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Circ Res 1993, 73:413-423.
44. Lorell BH, Grossman W: Cardiac hypertrophy: the consequences for diastole. J Am Coll Cardiol 1987, 9:1189-1193.
45. Brutsaert DL, Sys SU: Relaxation and diastole of the heart Physiol Rev 1989, 69:1228-1315.
46. 2+ handling is an early manifestation of pressure overload hypertrophy in rat hearts. Am J Physiol 1996, 271:H228-H234.
47. 2+ATPase in cardiac hypertrophy by angiotensin converting enzyme? Basic Res Cardiol 1992. 87 (suppl 2):191-204.
48. 2+ pumps in heart and diaphragm of cardiomyopathic hamster: effects of perindopril. Am J Physiol 1995, 268:H1947-H1953.
49. 2+ ATPase mRNA by angiotensin II in adult rat cardiomyocytes [abstract]. Circulation 1995, 92 (suppl 1):283.
50. Ohta K, Kim S, Wanibuchi H, Ganten D, Iwao H: Contribution of local renin-angiotensin system to cardiac hypertrophy, phenotypic modulation, and remodeling in TGR(mREN2)27 transgenic rats. Circulation 1996, 94:785-791.